JAK-mutant myeloproliferative neoplasms

Current Topics in Microbiology and Immunology

Volumn 355, Issue , 2012, Pages 119-133

  Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CYT 787; EXL 019; GUANINE; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; JANUS KINASE INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PROTEIN KINASE TYK2; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; STAT PROTEIN; THYMIDINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; ESSENTIAL THROMBOCYTOSIS; GENE; GENETIC PREDISPOSITION; HOMOZYGOSITY; HUMAN; LOSS OF FUNCTION MUTATION; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEUROTOXICITY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SOMATIC MUTATION; TET2 GENE; THROMBOCYTOPENIA; UNIPARENTAL DISOMY;

ALLELES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84865202724     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2011-170     Document Type: Article

References (81)

1. Abdel-Wahab O et al (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70:447-452
2. Abdel-Wahab O et al (2011a) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 19(5):769-780
3. Abdel-Wahab O et al (2011b) DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25:1219-1220
4. Akada H et al (2010) Conditional expression of heterozygous or homozygous JAK2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115(17):3589-3597
5. Argetsinger LS et al (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74:237-244
6. Baxter EJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
7. Beer PA et al (2009) Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 144:904-908
8. Bercovich D et al (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372:1484-1492
9. Boggon TJ, Li Y, Manley PW, Eck MJ (2005) Crystal structure of the JAK3 kinase domain in complex with a staurosporine analog. Blood 106:996-1002
10. Bumm TG et al (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66:11156-11165
11. Campbell PJ et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945-1953
12. Campbell PJ et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548-3555
13. Carbuccia N et al (2009a) Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 24(2):469-473
14. Carbuccia N et al (2009b) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183-2186
15. Chen E et al (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18:524-535
16. Cho YS, Kim EJ, Park UH, Sin HS, Um SJ (2006) Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 281:17588-17598
17. Delhommeau F et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301
18. Ding J et al (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198-4200
19. Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
20. Dusa A et al (2008) Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 283:12941-12948
21. Ernst T et al (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722-726
22. Figueroa ME et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567
23. Fisher CL et al (2010) Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 337:9-15
24. Flex E et al (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205:751-758
25. Gao SP et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846-3856
26. Gelsi-Boyer V et al (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788-800
27. Gross S et al (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339-344
28. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF (1992) JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7:1347-1353
29. Hedvat M et al (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497
30. Hexner EO et al (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111:5663-5671
31. James C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148
32. Jones AV et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446-449
33. Kilpivaara O et al (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455-459
34. Ko M et al (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-843
35. Koppikar P et al (2010) Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115(14):2919-2927
36. Kralovics R, Guan Y, Prchal JT (2002) Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30:229-236
37. Kralovics R et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
38. Lacout C et al (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652-1660
39. Landgren O et al (2008) Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199-2204
40. Langemeijer SM et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842
41. Levine RL et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
42. Ley TJ et al (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433
43. Li J et al (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 30(24):5741-5751
44. Lucet IS et al (2006) The structural basis of janus kinase 2 inhibition by a potent and specific panjanus kinase inhibitor. Blood 107:176-183
45. Marcucci G et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 28:2348-2355
46. Mardis ER et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066
47. Marty C et al (2010) Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116:783-787
48. Marubayashi S et al (2010) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120:3578-3593
49. Mesa RA et al (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105:973-977
50. Moran-Crusio K et al (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20(1):11-24
51. Mullally A et al (2010) Physiological JAK2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17:584-596
52. Mullighan CG et al (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106:9414-9418
53. Nikoloski G et al (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665-667
54. Oh ST et al (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116:988-992
55. Olcaydu D et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450-454
56. Pardanani AD et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1,182 patients. Blood 108:3472-3476
57. Pardanani A et al (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21:1658-1668
58. Pardanani A et al (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789-796
59. Parganas E et al (1998) JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93:385-395
60. Pikman Y et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270
61. Quivoron C et al (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 19(6):805-813
62. Rebouissou S et al (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457:200-204
63. Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of JAK2 and JAK3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277:47954-47963
64. Scott LM, Scott MA, Campbell PJ, Green AR (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108:2435-2437
65. Scott LM et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468
66. Shochat C et al (2011) Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 208:901-908
67. Tahiliani M et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930-935
68. Theocharides A et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110: 375-379
69. Tiedt R et al (2008) Ratio of mutant JAK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111:3931-3940
70. Tomasson MH et al (2008) Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111:4797-4808
71. Verstovsek S et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127
72. Wang Y et al (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114:5024-5033
73. Ward PS et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-234
74. Wernig G et al (2006) Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274-4281
75. Wernig G et al (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311-320
76. Witthuhn BA et al (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74:227-236
77. Xing S et al (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111:5109-5117
78. Yan XJ et al (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43(4):309-315
79. Yoda A et al (2009) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 107(1):252-257
80. Zaleskas VM et al (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1:e18
81. Zhao R et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792